<span item_type="fundamental" item_id="aece6da03efcaa065498728a2e41fde8" counter_id="ST/US/COCHW" env="prod"></span><span item_type="announcement" item_id="581232610759412097" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 42 K.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.35.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -5.237 M.</p><p></p><h3>Segment Revenue</h3><ul><li>Third quarter net revenue was $42 for the three months ended September 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025107898/ea026470901ex99-1_envoy.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Research and development (R&amp;D) expenses decreased by $57 to $2,700 for the three months ended September 30, 2025, compared to the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025107898/ea026470901ex99-1_envoy.htm"></span></li><li>General and administrative expenses increased by $752 for the three months ended September 30, 2025, primarily due to increased public company costs and expenses related to the September 2025 offering.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025107898/ea026470901ex99-1_envoy.htm"></span></li><li>Operating loss for the third quarter was - $5,708, compared to - $4,972 in the same period of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025107898/ea026470901ex99-1_envoy.htm"></span></li><li>Net loss for the third quarter was - $6,482, compared to - $5,960 in the same period of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025107898/ea026470901ex99-1_envoy.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities was - $12,516 for the nine months ended September 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025107898/ea026470901ex99-1_envoy.htm"></span></li><li>Cash at the end of the period was $3,556.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025107898/ea026470901ex99-1_envoy.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>Envoy Medical extinguished over $32 million in debt, strengthening its balance sheet.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025107898/ea026470901ex99-1_envoy.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Envoy Medical received FDA approval to expand its pivotal clinical trial to the final stage, indicating strong progress in its clinical trials. The company also successfully raised additional capital through a $16 million registered direct offering. Envoy Medical aims to increase its momentum as it finishes 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025107898/ea026470901ex99-1_envoy.htm"></span></li></ul>

ENVOY MEDICAL INC C/WTS 29/09/2028 (TO PUR COM) | 8-K: FY2025 Q3 Revenue: USD 42 K